Oramed Q3 2026: $134.9M Net Income on Alpha Tau Markup; Cash Falls to $28.9M
ORMP sits 79% above its 52-week low of $2.25.
Summary
Oramed posted $134.9M of nine-month net income driven by a $174.5M non-cash Alpha Tau revaluation gain, while cash fell to $28.9M and it added a new $9.0M mortgage guaranty.
Key Events · Earnings and Guidance · ORMP
-
Paper Profit From Alpha Tau Markup
Nine-month net income of $134.9M was driven by a $174.5M unrealized gain on the Alpha Tau stake, now worth $252.4M — about 63% of total assets.
-
Cash Falls to $28.9M
Cash and equivalents dropped from $45.9M at Dec 31, 2025 to $28.9M, after a $10.5M dividend and $11.9M deployed into the Lifeward transaction.
-
Deferred Tax Liability Jumps
Deferred tax liabilities rose to $50.1M from $7.9M, mainly tied to unrealized gains on the Alpha Tau investment.
-
New $9.0M Mortgage Guaranty
On Nov 6, 2026 Oramed joined a joint-and-several guaranty of a $9.0M Fieldpoint mortgage to MAR Bailey Avenue LLC, stepping down to 25% once a debt service coverage ratio is met.
Analysis · ORMP · Life Sciences
The headline profit is almost entirely paper: $174.5M of the $180.5M financial income came from marking up the Alpha Tau stake, which now sits at $252.4M — roughly 63% of total assets. That concentration is the real story. Cash dropped to $28.9M from $45.9M at year-end after a $10.5M dividend and $11.9M into the Lifeward deal, and deferred tax liabilities ballooned to $50.1M from $7.9M on those unrealized gains. In November the company also signed a new $9.0M joint-and-several guaranty on a Buffalo self-storage mortgage, adding off-balance-sheet exposure. With no revenue-generating operations after transferring the POD platform, Oramed is now effectively a leveraged bet on Alpha Tau's share price.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORMP was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $167.6M. The 52-week trading range was $2.25 to $5.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.